Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention
Sean C. Beinart, William S. Weintraub(Unknown), Jeanne Jackson(University of Southern California), J. Jaime(Chinese Academy of Medical Sciences & Peking Union Medical College), Paul Kolm(Christiana Care Health System), O Bouin(Sanofi (France)), Elizabeth M. Mahoney(Emory University), Eric J. Topol(Scripps Research Institute), Roland Chen(Bristol-Myers Squibb (Germany)), Zefeng Zhang(Centers for Disease Control and Prevention), Steven R. Steinhubl(Sorbonne Université), Sylvie Gabriel(Sanofi (France)), Emir Veledar(University of Miami)
Cited by 122
Related Papers
Long COVID: major findings, mechanisms and recommendations
|Nature Reviews Microbiology|2023|4k
Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden
|Circulation|2008|1.6k
A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial Infarction
|New England Journal of Medicine|1987|945
Model Transparency and Validation
|Medical Decision Making|2012|803
Effect of PCI on Quality of Life in Patients with Stable Coronary Disease
|New England Journal of Medicine|2008|732